Literature DB >> 10855737

A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.

M H Olsen1, U B Andersen, K Wachtell, H Ibsen, H Dige-Petersen.   

Abstract

BACKGROUND: We wanted to investigate whether insulin resistance and time to steady state during isoglycemic clamp were associated with endothelial dysfunction, peripheral vascular remodeling and forearm blood flow (FBF) in patients with longstanding hypertension.
METHODS: In 43 unmedicated, hypertensive patients with electrocardiographic-defined left ventricular hypertrophy we performed a 2-h oral glucose tolerance test and a 3-h isoglycemic hyperinsulinemic clamp with measurements of circulating plasma epinephrine and FBF by plethysmography. Delayed steady state was assessed by measuring the increase in insulin sensitivity from the second to the third hour of clamping. We measured 24-h ambulatory blood pressure, minimal forearm vascular resistance (MFVR) by plethysmography, media:lumen ratio (MLR) and acetylcholine-induced relaxation (AIR) in isolated, subcutaneous resistance arteries by myography.
RESULTS: Insulin sensitivity after 2 and 3 h of clamping was not related to maximal AIR, MLR, MFVR or FBF. The increase in insulin sensitivity in men was negatively correlated to maximal AIR (r = -0.36, p < 0.05), and was independently correlated to relative changes in FBF (beta = 0.46) and in circulating epinephrine (beta = 0.33; adj. R = 0.33, p < 0.001).
CONCLUSIONS: Insulin sensitivity was not correlated to parameters of peripheral vascular remodeling, endothelial function or microvascular rarefaction in patients with longstanding hypertension and left ventricular hypertrophy. However, the action of insulin on peripheral glucose uptake was influenced by endothelial dysfunction (delayed transcapillary insulin transport) and by changes in and/or redistribution of blood flow suggesting a link between vascular function and insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10855737     DOI: 10.1080/080370500453474

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  3 in total

1.  Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension.

Authors:  A A Lteif; R L Chisholm; K Gilbert; R V Considine; K J Mather
Journal:  Diabetes Obes Metab       Date:  2011-11-24       Impact factor: 6.577

Review 2.  Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

Authors:  André J Scheen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Authors:  Elizabeth Ripley; Ari Hirsch
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.